When will Newron report earnings and why does it matter for NWRN.SW stock?

Newron reports on 24 Mar 2026. The release matters because revenue updates for Xadago and clinical news for Evenamide and Ralfinamide can move NWRN.SW stock sharply, affecting short-term volatility and guidance expectations.

What price targets should investors watch for NWRN.SW stock?

Meyka AI suggests a quarterly target of CHF25.56 and a one-year target of CHF23.38 versus the current CHF15.62. Use these as model-based references, not guarantees, and monitor earnings for catalyst-driven revisions.

Is NWRN.SW stock a buy after the recent pullback?

Meyka AI assigns a B+ grade with a BUY suggestion based on growth metrics and forecasts. Investors should weigh pipeline risk, lack of dividend and earnings outcomes before buying; this is not financial advice.

What technical signals should traders monitor on NWRN.SW stock around earnings?

Key technicals are RSI at 24.29 (oversold), MACD negative, Bollinger lower band at CHF15.68, and ATR CHF1.08. These indicate elevated volatility and tight downside support into earnings.

CH Stocks

NWRN.SW Newron (SIX): pre-market CHF15.62 ahead of 24 Mar earnings, upside

ByDanny Kontos March 19, 2026March 19, 2026

NWRN.SW stock is trading pre-market at CHF15.62 as investors position ahead of Newron Pharmaceuticals S.p.A.’s earnings on 24 Mar 2026. The share is down 4.05% on the session from a previous close of CHF16.28, and technicals show an oversold reading that could amplify volatility around the report. We focus on the numbers investors will watch: revenue trends for Xadago, clinical updates on Evenamide and Ralfinamide, and guidance that could shift short-term price targets.